Baseline assessment includes standard recommendations plus the dosage of troponin and brain natriuretic peptide (BNP), together with echocardiogram among high-risk patients: they are subjects receiving dual ICI, combination ICI and cardiotoxic therapy, prior ICI-related non-CV events, and prior cancer therapy-related cardiac dysfunction or CV disease. The gene discussed is NPPB; the disease is cancer.